Overview

Pharmacokinetic and Efficacy Study of Nordihydroguaiaretic Acid (NDGA) in Non Metastatic Recurrent Prostate Cancer

Status:
Terminated

Trial end date:
2011-06-01

Target enrollment:

Participant gender:

Summary

This is a Phase II, single center study measuring the pharmacokinetic parameters of NDGA administration and assessing the proportion of patients who experience a 50% decline in PSA.

Phase:

Phase 2

Details

Lead Sponsor:

University of California, San Francisco

Collaborator:

Insmed Incorporated

Treatments:

Masoprocol